Literature DB >> 24939643

Oncogenic Ras/ERK signaling activates CDCP1 to promote tumor invasion and metastasis.

Takamasa Uekita1, Satoko Fujii2, Yuri Miyazawa2, Reika Iwakawa3, Mako Narisawa-Saito4, Katsuhiko Nakashima2, Koji Tsuta5, Hitoshi Tsuda5, Tohru Kiyono4, Jun Yokota3, Ryuichi Sakai6.   

Abstract

UNLABELLED: Involvement of Ras in cancer initiation is known, but recent evidence indicates a role in cancer progression, including metastasis and invasion; however, the mechanism is still unknown. In this study, it was determined that human lung cancer cells with Ras mutations, among other popular mutations, showed significantly higher expression of CUB domain-containing protein 1 (CDCP1) than those without. Furthermore, activated Ras clearly induced CDCP1, whereas CDCP1 knockdown or inhibition of CDCP1 phosphorylation by Src-directed therapy abrogated anoikis resistance, migration, and invasion induced by activated-Ras. Activation of MMP2 and secretion of MMP9, in a model of Ras-induced invasion, was found to be regulated through induction of phosphorylated CDCP1. Thus, CDCP1 is required for the functional link between Ras and Src signaling during the multistage development of human malignant tumors, highlighting CDCP1 as a potent target for treatment in the broad spectrum of human cancers associated with these oncogenes. IMPLICATIONS: CDCP1 protein induced by oncogenic Ras/Erk signaling is essential for Ras-mediated metastatic potential of cancer cells. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24939643     DOI: 10.1158/1541-7786.MCR-13-0587

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  32 in total

1.  CDCP1 cleavage is necessary for homodimerization-induced migration of triple-negative breast cancer.

Authors:  H J Wright; J Arulmoli; M Motazedi; L J Nelson; F S Heinemann; L A Flanagan; O V Razorenova
Journal:  Oncogene       Date:  2016-02-15       Impact factor: 9.867

2.  Inhibition of MEK, a canonical KRAS pathway effector in KRAS mutant NSCLC.

Authors:  Rafael Rosell; Niki Karachaliou; Carles Codony-Servat; Masaoki Ito
Journal:  Transl Lung Cancer Res       Date:  2018-09

3.  PP2A Inhibits Cervical Cancer Cell Migration by Dephosphorylation of p-JNK, p-p38 and the p-ERK/MAPK Signaling Pathway.

Authors:  Hong-Yun Zheng; Fu-Jin Shen; Yong-Qing Tong; Yan Li
Journal:  Curr Med Sci       Date:  2018-03-15

4.  The transcription factor HOXB7 regulates ERK kinase activity and thereby stimulates the motility and invasiveness of pancreatic cancer cells.

Authors:  Makiko Tsuboi; Keisuke Taniuchi; Takahiro Shimizu; Motoaki Saito; Toshiji Saibara
Journal:  J Biol Chem       Date:  2017-09-14       Impact factor: 5.157

5.  Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer.

Authors:  Anna Moroz; Yung-Hua Wang; Jeremy M Sharib; Junnian Wei; Ning Zhao; Yangjie Huang; Zhuo Chen; Alexander J Martinko; Jie Zhuo; Shion A Lim; Lydia H Zhang; Youngho Seo; Sean Carlin; Kevin K Leung; Eric A Collisson; Kimberly S Kirkwood; James A Wells; Michael J Evans
Journal:  Clin Cancer Res       Date:  2020-04-27       Impact factor: 12.531

6.  CrkL regulates SDF-1-induced breast cancer biology through balancing Erk1/2 and PI3K/Akt pathways.

Authors:  Xin Lian; Yu Jiao; Yu Yang; Zhipeng Wang; Qijia Xuan; Hang Liu; Shan Lu; Zunxian Wang; Yue Liu; Shuo Li; Yuguang Yang; Li Guo; Ling Zhao; Qingyuan Zhang
Journal:  Med Oncol       Date:  2014-12-05       Impact factor: 3.064

7.  CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease.

Authors:  Ning Zhao; Shalini Chopra; Kai Trepka; Yung-Hua Wang; Sasank Sakhamuri; Nima Hooshdaran; Hyunjung Kim; Jie Zhou; Shion A Lim; Kevin K Leung; Emily A Egusa; Jun Zhu; Li Zhang; Adam Foye; Renuka Sriram; Emily Chan; Youngho Seo; Felix Y Feng; Eric J Small; Jonathan Chou; James A Wells; Rahul Aggarwal; Michael J Evans
Journal:  Clin Cancer Res       Date:  2022-07-15       Impact factor: 13.801

8.  Effect of Cetuximab and EGFR Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type EGFR and Use of KRAS as a Possible Biomarker for Treatment Responsiveness.

Authors:  Naomi Miyake; Hiroki Chikumi; Kosuke Yamaguchi; Miyako Takata; Miki Takata; Kensaku Okada; Tsuyoshi Kitaura; Masaki Nakamoto; Akira Yamasaki
Journal:  Yonago Acta Med       Date:  2019-03-28       Impact factor: 1.641

9.  Endothelial k-RasV12 Expression Induces Capillary Deficiency Attributable to Marked Tube Network Expansion Coupled to Reduced Pericytes and Basement Membranes.

Authors:  Zheying Sun; Scott S Kemp; Prisca K Lin; Kalia N Aguera; George E Davis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-12-09       Impact factor: 8.311

10.  Prospective Identification of Elevated Circulating CDCP1 in Patients Years before Onset of Lung Cancer.

Authors:  Sonia Dagnino; Barbara Bodinier; Florence Guida; Karl Smith-Byrne; Dusan Petrovic; Matthew D Whitaker; Therese Haugdahl Nøst; Claudia Agnoli; Domenico Palli; Carlotta Sacerdote; Salvatore Panico; Rosario Tumino; Matthias B Schulze; Mikael Johansson; Pekka Keski-Rahkonen; Augustin Scalbert; Paolo Vineis; Mattias Johansson; Torkjel M Sandanger; Roel C H Vermeulen; Marc Chadeau-Hyam
Journal:  Cancer Res       Date:  2021-02-11       Impact factor: 13.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.